{"name":"Daewon Pharmaceutical Co., Ltd.","slug":"daewon-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"daewon.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"oncology","drugs":[{"name":"DW1026C2","genericName":"DW1026C2","slug":"dw1026c2","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW1026S","genericName":"DW1026S","slug":"dw1026s","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW1601","genericName":"DW1601","slug":"dw1601","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW51212","genericName":"DW51212","slug":"dw51212","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW5421A","genericName":"DW5421A","slug":"dw5421a","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DWKH","genericName":"DWKH","slug":"dwkh","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW1026C1","genericName":"DW1026C1","slug":"dw1026c1","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW16011","genericName":"DW16011","slug":"dw16011","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW16012","genericName":"DW16012","slug":"dw16012","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW1903","genericName":"DW1903","slug":"dw1903","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW1903-R1","genericName":"DW1903-R1","slug":"dw1903-r1","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DW5121","genericName":"DW5121","slug":"dw5121","indication":"Type 2 diabetes","status":"phase_3"},{"name":"DWKH-R","genericName":"DWKH-R","slug":"dwkh-r","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"DW340","genericName":"DW340","slug":"dw340","indication":"Other","status":"phase_1"},{"name":"DW51211","genericName":"DW51211","slug":"dw51211","indication":"Indication 1","status":"phase_3"},{"name":"Kremezin granule","genericName":"Kremezin granule","slug":"kremezin-granule","indication":"Other","status":"marketed"},{"name":"Test(DW1401)","genericName":"Test(DW1401)","slug":"test-dw1401","indication":"unknown","status":"phase_3"},{"name":"DW-0919","genericName":"DW-0919","slug":"dw-0919","indication":"Other","status":"phase_1"},{"name":"DW-0929","genericName":"DW-0929","slug":"dw-0929","indication":"Other","status":"phase_3"},{"name":"DW1809-T2","genericName":"DW1809-T2","slug":"dw1809-t2","indication":"Other","status":"phase_1"},{"name":"Placebo drug of DW-1030","genericName":"Placebo drug of DW-1030","slug":"placebo-drug-of-dw-1030","indication":"Other","status":"phase_3"},{"name":"Placebo drug of Myonal Tab.","genericName":"Placebo drug of Myonal Tab.","slug":"placebo-drug-of-myonal-tab","indication":"Control arm in Phase 3 clinical trials for muscle relaxation/spasticity (indication of active Myonal comparator)","status":"phase_3"},{"name":"Reference(Stillen tab.)","genericName":"Reference(Stillen tab.)","slug":"reference-stillen-tab","indication":"Hypothyroidism","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Telmisartan + Amlodipine","genericName":"Telmisartan + Amlodipine","slug":"telmisartan-amlodipine","indication":"Hypertension (essential hypertension)","status":"marketed"},{"name":"Telmisartan + Amlodipine + Rosuvastatin","genericName":"Telmisartan + Amlodipine + Rosuvastatin","slug":"telmisartan-amlodipine-rosuvastatin","indication":"Hypertension","status":"phase_3"},{"name":"DW-330SR2","genericName":"DW-330SR2","slug":"dw-330sr2","indication":"Hypertension","status":"phase_3"},{"name":"Telmisartan + Rosuvastatin","genericName":"Telmisartan + Rosuvastatin","slug":"telmisartan-rosuvastatin","indication":"Hypertension, Hyperlipidemia","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"GLA5PR GLARS-NF1","genericName":"GLA5PR GLARS-NF1","slug":"gla5pr-glars-nf1","indication":"Neurofibromatosis type 1 (NF1)-associated malignancies","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Renamezin capsule","genericName":"Renamezin capsule","slug":"renamezin-capsule","indication":"Bacterial infections (respiratory tract, urinary tract, and other infections)","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Tramadol hydrochloride/Acetaminophen Tab.","genericName":"Tramadol hydrochloride/Acetaminophen Tab.","slug":"tramadol-hydrochloride-acetaminophen-tab","indication":"Moderate to moderately severe acute pain","status":"phase_3"}]}],"pipeline":[{"name":"DW1026C2","genericName":"DW1026C2","slug":"dw1026c2","phase":"phase_3","mechanism":"DW1026C2 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DW1026S","genericName":"DW1026S","slug":"dw1026s","phase":"phase_3","mechanism":"DW1026S is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DW1601","genericName":"DW1601","slug":"dw1601","phase":"phase_3","mechanism":"DW1601 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DW340","genericName":"DW340","slug":"dw340","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DW51211","genericName":"DW51211","slug":"dw51211","phase":"phase_3","mechanism":"DW51211 is a small molecule drug that targets the molecular target.","indications":["Indication 1","Indication 2"],"catalyst":""},{"name":"DW51212","genericName":"DW51212","slug":"dw51212","phase":"phase_3","mechanism":"DW51212 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DW5421A","genericName":"DW5421A","slug":"dw5421a","phase":"phase_3","mechanism":"DW5421A is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DWKH","genericName":"DWKH","slug":"dwkh","phase":"phase_3","mechanism":"DWKH is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Kremezin granule","genericName":"Kremezin granule","slug":"kremezin-granule","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Telmisartan + Amlodipine","genericName":"Telmisartan + Amlodipine","slug":"telmisartan-amlodipine","phase":"marketed","mechanism":"Telmisartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.","indications":["Hypertension (essential hypertension)"],"catalyst":""},{"name":"Telmisartan + Amlodipine + Rosuvastatin","genericName":"Telmisartan + Amlodipine + Rosuvastatin","slug":"telmisartan-amlodipine-rosuvastatin","phase":"phase_3","mechanism":"Telmisartan is an angiotensin II receptor antagonist, amlodipine is a calcium channel blocker, and rosuvastatin is a statin.","indications":["Hypertension","Hyperlipidemia"],"catalyst":""},{"name":"Test(DW1401)","genericName":"Test(DW1401)","slug":"test-dw1401","phase":"phase_3","mechanism":"Test(DW1401) is a small molecule drug that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"DW-0919","genericName":"DW-0919","slug":"dw-0919","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DW-0929","genericName":"DW-0929","slug":"dw-0929","phase":"phase_3","mechanism":"DW-0929 is an investigational therapeutic agent in phase 3 development by Daewon Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"DW-330SR2","genericName":"DW-330SR2","slug":"dw-330sr2","phase":"phase_3","mechanism":"DW-330SR2 is a small molecule that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"DW1026C1","genericName":"DW1026C1","slug":"dw1026c1","phase":"phase_3","mechanism":"DW1026C1 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DW16011","genericName":"DW16011","slug":"dw16011","phase":"phase_3","mechanism":"DW16011 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DW16012","genericName":"DW16012","slug":"dw16012","phase":"phase_3","mechanism":"DW16012 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DW1809-T2","genericName":"DW1809-T2","slug":"dw1809-t2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DW1903","genericName":"DW1903","slug":"dw1903","phase":"phase_3","mechanism":"DW1903 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DW1903-R1","genericName":"DW1903-R1","slug":"dw1903-r1","phase":"phase_3","mechanism":"DW1903-R1 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DW5121","genericName":"DW5121","slug":"dw5121","phase":"phase_3","mechanism":"DW5121 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DWKH-R","genericName":"DWKH-R","slug":"dwkh-r","phase":"phase_3","mechanism":"DWKH-R is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"GLA5PR GLARS-NF1","genericName":"GLA5PR GLARS-NF1","slug":"gla5pr-glars-nf1","phase":"phase_3","mechanism":"GLA5PR GLARS-NF1 is a glutaminyl-tRNA synthetase (GlnRS) inhibitor designed to selectively target and inhibit neurofibromatosis type 1 (NF1) mutant cells.","indications":["Neurofibromatosis type 1 (NF1)-associated malignancies","NF1-associated plexiform neurofibromas"],"catalyst":""},{"name":"Placebo drug of DW-1030","genericName":"Placebo drug of DW-1030","slug":"placebo-drug-of-dw-1030","phase":"phase_3","mechanism":"Placebo drugs do not have an active pharmacological mechanism; they are used as controls in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo drug of Myonal Tab.","genericName":"Placebo drug of Myonal Tab.","slug":"placebo-drug-of-myonal-tab","phase":"phase_3","mechanism":"As a placebo, this drug contains no active pharmaceutical ingredient and produces no mechanistic effect beyond the placebo response.","indications":["Control arm in Phase 3 clinical trials for muscle relaxation/spasticity (indication of active Myonal comparator)"],"catalyst":""},{"name":"Reference(Stillen tab.)","genericName":"Reference(Stillen tab.)","slug":"reference-stillen-tab","phase":"phase_3","mechanism":"Stillen is a medication used to treat hypothyroidism.","indications":["Hypothyroidism"],"catalyst":""},{"name":"Renamezin capsule","genericName":"Renamezin capsule","slug":"renamezin-capsule","phase":"marketed","mechanism":"Renamezin is an antibiotic that inhibits bacterial protein synthesis by binding to the bacterial ribosome.","indications":["Bacterial infections (respiratory tract, urinary tract, and other infections)"],"catalyst":""},{"name":"Telmisartan + Rosuvastatin","genericName":"Telmisartan + Rosuvastatin","slug":"telmisartan-rosuvastatin","phase":"phase_3","mechanism":"Telmisartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering LDL cholesterol.","indications":["Hypertension, Hyperlipidemia"],"catalyst":""},{"name":"Tramadol hydrochloride/Acetaminophen Tab.","genericName":"Tramadol hydrochloride/Acetaminophen Tab.","slug":"tramadol-hydrochloride-acetaminophen-tab","phase":"phase_3","mechanism":"Tramadol inhibits norepinephrine and serotonin reuptake while acting as a weak opioid agonist, and acetaminophen reduces pain through central analgesic and antipyretic effects.","indications":["Moderate to moderately severe acute pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE1kamc3STMxanJzejl5X0I2d19zbzBpVEIyV1JIUG9Qemc3dzEtZTJudGlzX1hyYTRNc3ZPaGJkZk5leWdTLXlKSDRzSnFCNXRtTjVqVW13RdIBV0FVX3lxTE1kamc3STMxanJzejl5X0I2d19zbzBpVEIyV1JIUG9Qemc3dzEtZTJudGlzX1hyYTRNc3ZPaGJkZk5leWdTLXlKSDRzSnFCNXRtTjVqVW13RQ?oc=5","date":"2026-04-02","type":"pipeline","source":"aju press","summary":"Korean Pharma-Bio Briefing: Kolon Life Science, Daewoong, Celltrion, Daewon, Samsung Medical Center - aju press","headline":"Korean Pharma-Bio Briefing: Kolon Life Science, Daewoong, Celltrion, Daewon, Samsung Medical Center","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE91X3YzSzcwLUNzTXFKWDVINGd6S3ZxZ2FxRzcxR3h6UU5IVkx6aDFMTW95aGg0OTBfS0lGMVRRZ3piRTVFYWZoNmJRbnZsX2tlMm1lN0gydThncXhIR1pkMGhaMXdVbThzQXpYUXlB0gFyQVVfeXFMTUxkUFJ3RUFBQXgzS1FOLVI3SlVIUUV5VTVIaFd3VGN3MnBkc3pxUTFOQ0JjS0ZSVURjc1hrTzZZWEhBdkRzdVUtWHQwUWtOV0RfeTVOc2cyeFFXT3FyNXR3MVVwZ2h3b0hqODdrZjVxdURB?oc=5","date":"2026-01-16","type":"trial","source":"koreabiomed.com","summary":"Daewon Pharm opens phase 3 study of reflux candidate in NERD as it runs parallel ERD program - koreabiomed.com","headline":"Daewon Pharm opens phase 3 study of reflux candidate in NERD as it runs parallel ERD program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPek5PVDFib1g3emxSQy1tMFNfNGpDY1RIc3FnaEhpbUVDOVU3cHI1Vm80TU55OGFPdTFCQVl6MzBBbS1qQnNaWDI3dHlpQVMtdnNYRll2akM5N1RWZFhsTUxESXdXWVNuRDR0cmo3TUt4S0RRdUxJU3BNSUFaZExxctIBlAFBVV95cUxNalpqSVVjZnlraEM4eXpyQVBVMkpUVk9uODdibnhqTDVweW52ZW5CQkl4aWJxQXFVR3puSkVZT3htRnU4blRKVDF1aXlSRndHeGU1OVFKWXE5WTE5enhGaXRhLXZ3TTZFTDJtT1VDOTFzRjZZYVBQV3RidnJQMnZzcFZ3ZnhVaUFvZUpCZjNFLWJIbTFI?oc=5","date":"2025-07-07","type":"pipeline","source":"Chosunbiz","summary":"Daewon Pharmaceutical leads antidiarrheal sales with Potagel for five years - CHOSUNBIZ - Chosunbiz","headline":"Daewon Pharmaceutical leads antidiarrheal sales with Potagel for five years - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNVzk3RUZNRC1NZWxoNXBfNTNXTzFhdjZ2QU5ORmJFaXowQUtQcDlZeGRxbDB6VDI1T19HZXRzNV9DQlRueE8wNDV1ajhKcUNCUlhhMHYydWZxWjZzQkd4UDZSbVJCWlNTOUdvNjFzVFZwMXRuUzg5RnJCNHN5Qjk5WXNWeE1SWmRybzAyZ3lDbjAtVUVURG54WXllT083VjFGUV81YkxtQjlYMS01a1FKZnpDX3hKVWo5b19NMHl6OWFLbW1seDdaTE51WnJPdzJ1NEhkYmFpTWdyVHRBUmdfc2hETGFEUFFGVlo4MWNyUGUtNHE3ckQzUWM4WldxNUtUYm9ZT0QydjhydTA5Nmc?oc=5","date":"2025-05-07","type":"trial","source":"prnewswire.com","summary":"TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - prnewswire.com","headline":"TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterin","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9IbWZCcnFzSUtDU2dFVnhhUmhZaUtXQlB2M212UEhjdmJzbnhlVG5pS1BXMVhueHB4dzV6OVlYNUdGN2ZlTmRWbi1zbGhmWDd1MnVqOUxBQWN4dUdSVERtUUd1ODh6OEJVbi1pc3Fn0gFyQVVfeXFMT1k5WU1KeDVoMURBVWg5dWFlY3VPYU9obzRXelAtd3FKUDN4aktlck5DRC13b2c3TnB3b0xxcllSZXVNTTZ3b0phdmI1eTlNbUxIRXBBcVMyVjRSbDdOZ3hYRDRPWk1OSXdhSFgxNFEwaXNn?oc=5","date":"2025-02-05","type":"pipeline","source":"koreabiomed.com","summary":"Daewon Pharmaceutical to distribute AstraZeneca Korea’s asthma treatments - koreabiomed.com","headline":"Daewon Pharmaceutical to distribute AstraZeneca Korea’s asthma treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPVzl2OHh1Q0RsNVBTd2NkQS1MdE51NVVSQ2JsdlhtWWtXM1N6b3YtTXpvUEpVSk1SYkltTUlkbDZsMjM5SnE4Zm9VRDBSVWpQRVkyUkJNYTFnNWprZUwtSzFSWTItZEt3SF84bFdxajZwS1FlaGd1REFVWFlyaDBjOFJWUXllVV9SbE95MkUzNXRuMEVLVk9B?oc=5","date":"2023-12-12","type":"pipeline","source":"BioWorld News","summary":"South Korea anticipates drug pricing reform in 2024 - BioWorld News","headline":"South Korea anticipates drug pricing reform in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA5RnZiUFhLdHEwY2o4TEtVd2xobXdaTFFuQ2NEZzRqU2FEVnJkQ2JyRjROM0Q0cnFMLU83QkV6QlE4eTk2N2xURkdBVE1qdm9xQ2dCNGhTRUIxYXhQTW82djYyXzh5SXloOXd5eF9B0gFyQVVfeXFMUEs0cDB2NWNnRk0xR19HU0dmWkFaWjJDbm9HSXNMZHdnRlk3dVBuV1R5dVQzTk0yLXl6OUFmM3J2X01YMjVqTnA2TzFKRjNfdTJ5QmJHa1NUbEN1VDJ6UWhZdm84VUdqbWpRTXp6WHpaRDl3?oc=5","date":"2023-10-11","type":"pipeline","source":"koreabiomed.com","summary":"New drug mispackaging incident hits 2 pharma firms - koreabiomed.com","headline":"New drug mispackaging incident hits 2 pharma firms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE11NWtSZEk5WlFIOHVWTzZzZGc5Nk9QWXVzUDNENGlVd0xFTzhDazgyVWxXeF92VEpjVXdHMlRibGZmYkdJZllhc1pqNjRnZGpJNDVaUzlxVmVLSEJvMmV4ZHFqZ0tjMC1tR1lxd1p3?oc=5","date":"2023-09-25","type":"pipeline","source":"KED Global","summary":"Daewon Pharma to export $3 mn worth of Pelubi to Indonesia - KED Global","headline":"Daewon Pharma to export $3 mn worth of Pelubi to Indonesia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBUbGhKUXRwZlZSZzNBYU5jQVVuTm1LWVdRaC0yLTNPZ2RyUE12emgtV3dDRVpUTnRtSWJIM3QxbWdkQlZzcVNZcEJkeWRBdmNTemZzZEhzbHd1d3VpcGU5VHo4LTF3dmozM2dGZDhn0gFyQVVfeXFMUDBMWUZuVjFWWFVJQWlNYjdnNGw3MUJhRy01d1VxdlQ4aEgwUVVPSExIZlZDS0FXQTlmYm5DMXhNZ1lGcWJKV3FXZG1vV3UzNW53ZlNtOFFidTFOQTA0MUtkaWFOZnhudkFLcXpDSkY1N3hB?oc=5","date":"2021-03-05","type":"pipeline","source":"koreabiomed.com","summary":"Daewoong launches sustained-release rebamipide gastritis treatment - koreabiomed.com","headline":"Daewoong launches sustained-release rebamipide gastritis treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQb2tsOS1iakx0QTYyN3N5YWN6T1g5SlJ5bGJ4SUVERlZueHczXzQteEh0Y1UyVURiVzFoVVU0eUdsZUJOQVFfM29JSzRVMllQdXpCOThpVFQ5WEp1ZnV4dWhhQ3I1T2dKdE5ZQ3NVVlhYR0NDYjhIOXU1ZG05OGdlUDM5VXlXdXJUUng3NFN4bTVpVkY5SWJPa2F0blY2QQ?oc=5","date":"2020-05-19","type":"patent","source":"BioWorld News","summary":"Daewon Pharma launches its first teriparatide biosimilar - BioWorld News","headline":"Daewon Pharma launches its first teriparatide biosimilar","sentiment":"neutral"}],"patents":[],"drugCount":30,"phaseCounts":{"phase_3":24,"phase_1":3,"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}